Trials / Completed
CompletedNCT00947687
Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects
A Randomized, Phase 1B, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Pulmatrix Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The objectives of the study are to demonstrate the effectiveness, safety and tolerability of multiple daily doses of inhaled PUR003, in comparison with placebo, in healthy adults experimentally inoculated with Influenza A/Wisconsin/67/2005 (H3N2) virus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PUR003 | Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days |
| DRUG | Placebo |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2009-09-01
- Completion
- 2009-10-01
- First posted
- 2009-07-28
- Last updated
- 2017-09-19
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00947687. Inclusion in this directory is not an endorsement.